This study evaluates the biodistribution and tumor-targeting efficacy of 89Zirconium-labeled CI-8993, a monoclonal antibody against V-domain Ig suppressor of T-cell activation (VISTA), using positron emission tomography (PET) imaging. The research aims to visualize and quantify VISTA expression in vivo, providing insights into the potential of CI-8993 as an immunotherapeutic agent.
PET imaging revealed specific accumulation of 89Zr-labeled CI-8993 in VISTA-expressing tissues and tumors, indicating effective targeting. The study demonstrates the feasibility of using radiolabeled CI-8993 for non-invasive imaging of VISTA expression, supporting its potential utility in patient stratification and monitoring responses to VISTA-targeted therapies.
The study utilized a humanized VISTA Knockin mouse model developed in collaboration with genOway. This model expresses human VISTA in place of the murine counterpart, allowing for the assessment of human-specific antibody interactions and the evaluation of CI-8993's targeting capabilities in a physiologically relevant setting.
Immuno-oncology, Immune checkpoint inhibition, Molecular imaging, Monoclonal antibody therapy, Tumor immunology
Humanized Knockin model, Radiolabeling, PET imaging, In vivo antibody distribution, Immune checkpoint targeting
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
